Transition From Psoriasis to Psoriatic Arthritis is Characterized by Distinct Alterations in Peripheral Blood Tc17, Th17, and CD4 + Effector Memory Cells
Year: 2025
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: Cellular mechanisms driving transition from psoriasis to psoriatic arthritis have remained largely elusive. Thus, we investigated changes within the peripheral blood T cell compartment associated with the transition phase. METHODS: In an observational study, 116 patients were examined and categorized into subgroups including psoriasis with at least one risk factor for transition to psoriatic arthritis, subclinical psoriatic arthritis according to EULAR taskforce recommendations from 2023, and definitive psoriatic arthritis meeting the Classification Criteria for Psoriatic Arthritis. Demographic and clinical characteristics of patient subgroups were analyzed. Deep T cell phenotyping using multicolor flow cytometry and machine-learning techniques were applied. RESULTS: T cells, Th17, and Tc17 cells differed among patients with psoriasis with at least one risk factor for transition, subclinical psoriatic arthritis, and psoriatic arthritis. Transition-associated changes of Tc17 cell frequencies were confirmed by machine-learning-assisted unsupervised clustering analysis. Moreover, patients with enthesitis could be distinguished from those without, with Tc17 cells being the main distinctive feature. CONCLUSION: Transition from psoriasis to psoriatic arthritis was associated with distinct alterations of the peripheral blood T cell compartment, with Tc17 cells exhibiting the greatest discriminatory power. These findings provide insight into pathomechanisms driving disease progression during transition from psoriasis to psoriatic arthritis and identify Tc17 cells as the foremost novel potential therapeutic target for the prevention of transition.
Source: Arthritis & Rheumatology
DOI: 10.1002/art.43396
Authors: Hanna Graßhoff, Sara Comdühr, Henry Nording, Jacob von Esebeck, Philine Letz, Miriam Prohaczka, Handan Gedik, Henner Zirpel, Elisabeth Spallek, Linh Ha‐Wissel, El‐Baraa Adjailia, Sabrina Arnold, Konstantinos Fourlakis, Sebastian Klapa, Ingo Eitel, Oliver J. Müller, Jens Y. Humrich, Gabriela Riemekasten, Diamant Thaçi, Peter Lamprecht
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Regeneron Pharmaceuticals, Celltrion, European Commission, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Daiichi-Sankyo, Bundesministerium der Verteidigung, Vifor Pharma, Galderma, LEO Pharma, Chugai Pharmaceutical, HORIZON EUROPE Framework Programme, UCB Pharma, Cilag
Awards: G165400314, G5084497263, G6167187853
OpenAlex ID: W4414247193
